Kinase inhibitors are now standard treatment for patients with lung cancer whose tumors harbor specific mutant kinases. Four recent studies, including three in this issue (pages 375–384), have identified new fusion proteins involving another receptor tyrosine kinase that may potentially be responsive to existing targeted therapies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Comprehensive molecular profiling of pulmonary pleomorphic carcinoma
npj Precision Oncology Open Access 22 June 2021
-
Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling
BMC Cancer Open Access 12 October 2020
-
The role of RICTOR amplification in targeted therapy and drug resistance
Molecular Medicine Open Access 10 February 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jemal, A. et al. CA Cancer J. Clin. 61, 69–90 (2011).
Pao, W. & Girard, N. Lancet Oncol. 12, 175–180 (2011).
Li, C. et al. PLoS ONE 6, e28204 (2011).
Pao, W. et al. Proc. Natl. Acad. Sci. USA 101, 13306–13311 (2004).
Kwak, E.L. et al. N. Engl. J. Med. 363, 1693–1703 (2010).
Bergethon, K. et al. J. Clin. Oncol. published online, 10.1200/JCO.2011.35.6345 (3 January 2012).
Kohno, T. et al. Nat. Med. 18, 375–377 (2012).
Lipson, D. et al. Nat. Med. 18, 382–384 (2012).
Takeuchi, K. et al. Nat. Med. 18, 378–381 (2012).
Ju, Y.S. et al. Genome Res. published online, 10.1101/gr.133645.111 (22 December 2011).
Takahashi, M., Ritz, J. & Cooper, G.M. Cell 42, 581–588 (1985).
Phay, J.E. & Shah, M.H. Clin. Cancer Res. 16, 5936–5941 (2010).
Chmielecki, J. et al. Nucleic Acids Res. 38, 6985–6996 (2010).
Ciampi, R. & Nikiforov, Y.E. Endocrinology 148, 936–941 (2007).
Wells, S.A. Jr. et al. J. Clin. Oncol. 28, 767–772 (2010).
Sablin, E.P. Curr. Opin. Cell Biol. 12, 35–41 (2000).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
W.P. is a consultant for MolecularMD, AstraZeneca, Bristol-Myers Squibb, Sequencing Evolution and Clovis Oncology and received research funding from Enzon, Xcovery, AstraZeneca and Symphogen. The rights to EGFR T790M testing were licensed on behalf of W.P. and others by Memorial Sloan-Kettering Cancer Center to MolecularMD.
Rights and permissions
About this article
Cite this article
Pao, W., Hutchinson, K. Chipping away at the lung cancer genome. Nat Med 18, 349–351 (2012). https://doi.org/10.1038/nm.2697
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2697
This article is cited by
-
Gene expression profiling using targeted RNA-sequencing to elucidate the progression from histologically normal lung tissues to non-invasive lesions in invasive lung adenocarcinoma
Virchows Archiv (2022)
-
Comprehensive molecular profiling of pulmonary pleomorphic carcinoma
npj Precision Oncology (2021)
-
Identification of common signatures in idiopathic pulmonary fibrosis and lung cancer using gene expression modeling
BMC Cancer (2020)
-
The role of RICTOR amplification in targeted therapy and drug resistance
Molecular Medicine (2020)
-
MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-β pathway in NSCLC
Oncogene (2019)
